Keeping S3 ad restrictions keeps consumers in the dark: ASMI


ASMI is disappointed with the Government’s decision to retain S3 advertising restrictions and to replace  the current mandatory advertising pre-approvals system with a self-regulatory system, it says.

In welcoming the Government’s decision to accept most of the Sansom Review’s recommendations, ASMI said it was “great to have some clarity at last as to the Government’s position,” but that it was disappointed about the two advertising proposals.

“Industry is pleased the Federal Government will reform the scheduling framework for non-prescription medicines,” says ASMI CEO Deon Schoombie.

“The current system does not optimise consumer access to medicines or incentivise innovation and investment, and reform is long overdue.

“There is an opportunity to expand consumer access to more OTC medicines, thereby improving public health and providing much needed savings to the healthcare budget in the future.”

He says ASMI supports the Government’s decisions on the regulation of complementary medicines.

“Industry has long advocated for a risk-based approach to regulation and the Government has accepted many of the proposals industry put forward in its submissions to address the acknowledged shortcomings in the current system. We look forward to participating in the reform process.

“We are disappointed that at this point in time the Government has taken no action to remove restrictions on the advertising of S3 medicines.

“It is difficult to see the public health benefits of keeping consumers in the dark about the availability of safe and efficacious medicines, especially when pharmacists are the gatekeepers of this product schedule with mandatory counselling required prior to the sale of these medicines.”

He says ASMI will continue its advocacy for S3 consumer advertising reforms and will be shortly bringing to government research generated by the University of Technology’s Centre for Health Economic Research and Evaluation which supports the case that consumer advertising of S3’s drives better quality use of medicines outcomes for consumers.

“ASMI also opposes the Government’s decision to replace the current mandatory advertising pre-approvals system with a self-regulatory system,” Dr Schoombie says.

“ASMI believes the mandatory pre-approval of advertisements provides a high level of consumer protection and it also provides for a level playing field for manufacturers.

“There is clear and compelling evidence that the pre-approval of advertisements ensures high levels of compliance and protects consumers from non-compliant advertising.

“ASMI advocates for a complaints system that is fair, efficient, effective, transparent and applies to all advertisers and all media. There should be one body that receives and determines complaints about advertising directed to consumers and there should be a single body to receive and determine complaints.”

Previous Weekly Dose: cannabis has been used medicinally for millennia, why is legalising it taking so long?
Next Site applications for SHPA Residency Program open

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.